Soleno Therapeutics Reports Q1 2025 Results and VYKAT XR Launch

Soleno Therapeutics ( (SLNO) ) has released its Q1 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its investors.

Soleno Therapeutics, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for treating rare diseases, with its first commercial product being VYKAT XR for Prader-Willi syndrome. In its latest earnings report, Soleno announced the U.S. FDA approval and launch of VYKAT XR, marking a significant milestone for the company. The launch has seen positive initial uptake with 268 patient start forms and 131 unique prescribers. Financially, Soleno reported a net loss of $43.8 million for the first quarter of 2025, with no revenue generated yet from VYKAT XR as commercialization commenced post-quarter end. Despite the losses, Soleno maintains a strong cash position of $290 million, which supports its ongoing commercial and development activities. Looking ahead, Soleno is optimistic about expanding VYKAT XR’s market presence and achieving significant milestones, including a Marketing Authorization Application submission to the European Medicines Agency.